![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5944/TOC-Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})
Abstract
Objective: The prognostic function of neurite growth-promoting factor 2 (Midkine (MK)) in adjuvant treatment of head and neck squamous cell carcinoma (HNSCC) is unclear. This study examined whether MK expression may predict treatment response and survival in resectable HNSCC patients.
Methods: In this retrospective study, MK expression in 144 HNSCC patients was analyzed by immunohistochemistry. A subset of patients (n = 10) had MK expression levels analyzed by western blot and semi-quantitative reverse transcription polymerase chain reaction. Data were analyzed using the Log-rank test and α = 0.05.
Results: Expression of MK was associated with poorer five-year progression-free and overall survival rates in HNSCC patients (p = 0.002).
Conclusion: MK might play an important role in the progression of HNSCC and may be a useful prognostic factor.
Acknowledgements
T.J.C. and C.H.C. conceived the study design, carried out and coordinated immunohistochemical examinations of tumor specimens and data analysis, and drafted the manuscript. C.Y.C. and H.T.T. participated in the interpretation of data and conducted immunohistochemistry analysis. S.H.L. and K.M.R. collected the clinical data of patients and performed statistical data analysis. Y.J.C. and H.L.E. coordinated the study and were involved in drafting the manuscript and revised it critically. All authors read and approved the final manuscript.
